Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: A controlled propensity-matched analysis of a French multicenter cohort

Abstract

Background. The standard of care for newly diagnosed glioblastoma is maximal safe surgical resection, followed by chemoradiation therapy. We assessed carmustine wafer implantation efficacy and safety when used in combination with standard care. Me th od s. Included were adult patients with (n = 354, implantation group) and without (n = 433, standard group) carmustine wafer implantation during first surgical resection followed by chemoradiation standard protocol. Multivariate and case-matched analyses (controlled propensity-matched cohort, 262 pairs of patients) were conducted. Results. The median progression-free survival was 12.0 months (95% CI: 10.712.6) in the implantation group and 10.0 months (9.010.0) in the standard group and the median overall survival was 20.4 months (19.022.7) and 18.0 months (17.019.0), respectively. Carmustine wafer implantation was independently associated with longer progression-free survival in patients with subtotal/total surgical resection in the whole series (adjusted hazard ratio [HR], 0.76 [95% CI: 0.630.92], P =.005) and after propensity matching (HR, 0.74 [95% CI: 0.600.92], P =.008), whereas no significant difference was found for overall survival (HR, 0.95 [0.801.13], P =.574; HR, 1.06 [0.871.29], P =.561, respectively). Surgical resection at progression whether alone or combined with carmustine wafer implantation was independently associated with longer overall survival in the whole series (HR, 0.58 [0.440.76], P